高密度脂蛋白(HDL)抗动脉粥样硬化研究进展  

Research advances in anti-atherosclerosis of high-density lipoprotein(HDL)

作　　者：董继斌[1] 吴满平[1] 

机构地区：[1]复旦大学药学院生物化学教研室,上海201203

出　　处：《复旦学报（医学版）》2012年第4期414-417,共4页Fudan University Journal of Medical Sciences

摘　　要：血浆高密度脂蛋白(high-density lipoprotein,HDL)通过其载脂蛋白A-I(apolipoprotein A-I,ApoA-I)介导胆固醇逆向转运,呈现抗动脉粥样硬化(atherosclerosis,AS)功能。近来大量研究结果显示高密度脂蛋白的多种抗AS、抗炎功能与胆固醇代谢无关,而是由其联结的鞘氨醇-1-磷酸(sphingosine 1-phosphate,S1P)和ApoA-I分别通过S1P受体和清道夫受体B-I(scavenger receptor class BI,SR-BI)介导的细胞内信号通路来实现。It is well known that anti-atherogenic actions of high-density lipoprotein（HDL） are thought to be reverse cholesterol transport through its associated apolipoprotein A-I（ApoA-I）.Recently mounting evidence indicates that multiple anti-atherogenic or anti-inflammatory actions of HDL independent of cholesterol metabolism are mediated by HDL-associated sphingosine 1-phosphate（S1P） through S1P receptors and by ApoA-I through scavenger receptor class BI（SR-BI）.

关 键 词：高密度脂蛋白(HDL) 载脂蛋白A-I(ApoA-I) 鞘氨醇-1-磷酸受体(S1P) 清道夫受体B-I(SR-BI) 动脉粥样硬化(AS) 

分 类 号：R963[医药卫生—微生物与生化药学]